Evidence of renal metabolism of ifosfamide to nephrotoxic metabolites

doi:10.1016/S0024-3205(00)00915-2

Life Sciences

Volume 68, Issue 1, 24 November 2000, Pages 109-117

https://doi.org/10.1016/S0024-3205(00)00915-2 Get rights and content

Abstract

Nephrotoxicity is a limiting factor in the use of ifosfamide in children. Despite the co-administration of uroprotective agents such as sodium 2-mercaptoethanesulfonate (mesna), ifosfamide chemotherapy is associated with nephropathy characterized by glomerular toxicity and Fanconi syndrome in many children treated with this drug. This is in distinction to cyclophosphamide, an analogue which differs solely by the position of a chloroethyl group, and which is not associated with nephrotoxicity. We hypothesized that ifosfamide is metabolized by cytochrome P450 (CYP) enzymes located in the renal tubular cell to the toxic metabolite chloroacetaldehyde; and, that the higher production of chloroacetaldehyde from ifosfamide than from cyclophosphamide explains the clinical differences in nephrotoxicity. We found that in both pig renal cortical microsomes and whole human kidney microsomes incubated with 1 mM ifosfamide for 3 hr, 2 and 3 dechloroethylifosfamide (DCEI) were produced.Our study provides evidence that porcine and human kidney microsomes are capable of biotransforming ifosfamide to DCEI metabolites that are produced in equimolar amounts with chloroacetaldehyde, indicating that chloroacetaldehyde is locally produced by renal cells as a possible mechanism for nephrotoxicity.

References (0)

Cited by (57)

Tinospora cordifolia ameliorates urotoxic effect of cyclophosphamide by modulating GSH and cytokine levels
2012, Experimental and Toxicologic Pathology
Citation Excerpt :
It is not cytotoxic by itself but undergoes activation through a metabolic step In vivo. Numerous metabolites are known (Woodland et al., 2000; Kerbusch et al., 2001) and the major ones are chloroethylazairidin, acrolein and 4-hydroxy cyclophosphamide produced by the mixed function of cytochrome p450 oxidase present in hepatic microsomes (Dumontet et al., 2001). These metabolites are excreted in the urine.
Cyclophosphamide (CP) is a commonly used anti-cancer drug which causes toxicity by its reactive metabolites. In this study we investigated the effect of Tinospora cordifolia on urotoxicity induced by acute dose of CP using Swiss albino mice model. Administration of an alcoholic extract of the plant T. cordifolia (Family: Menispermaceae) (200 mg/kg i.p.) for 5 days reduced CP (1.5 mmol/kg body wt. i.p.) induced urotoxicity as evident from the morphological analysis of bladder, decreased the relative bladder and liver weights and also decreased level of urea nitrogen and protein in blood as well as urine. Severely inflamed and dark coloured urinary bladders of the CP alone treated animals were found to be normalized by the treatment of T. cordifolia. GSH content, which was drastically reduced by CP administration in both bladder and liver was enhanced by treatment with T. cordifolia. Histopathological analysis of the bladder of CP alone-treated group showed severe necrotic damage where as the T. cordifolia-treated group showed normal bladder architecture. The lowered levels of cytokines IFN-γ, IL-2, after CP treatment were found to be increased in treated animals. At the same time the level of pro-inflammatory cytokine TNF-α, which was elevated during CP administration, was significantly reduced by extract administration. This study clearly demonstrates uroprotective role of T. cordifolia from CP induced toxicities by modulating GSH and pro-inflammatory cytokine levels.
Comparative metabolism of cyclophosphamide and ifosfamide in the mouse using UPLC-ESI-QTOFMS-based metabolomics
2010, Biochemical Pharmacology
Citation Excerpt :
The current findings suggest that IF-induced side effects may result directly from CAA rather than from SCMC and TDGA. Studies have reported that CAA can result in neurotoxicity and nephrotoxicity [50,51]. This observation may offer one potential mechanism to explain IF-related neurotoxicity and nephrotoxicity.
Ifosfamide (IF) and cyclophosphamide (CP) are common chemotherapeutic agents. Interestingly, while the two drugs are isomers, only IF treatment is known to cause nephrotoxicity and neurotoxicity. Therefore, it was anticipated that a comparison of IF and CP drug metabolites in the mouse would reveal reasons for this selective toxicity. Drug metabolites were profiled by ultra-performance liquid chromatography-linked electrospray ionization quadrupole time-of-flight mass spectrometry (UPLC–ESI-QTOFMS), and the results analyzed by multivariate data analysis. Of the total 23 drug metabolites identified by UPLC–ESI-QTOFMS for both IF and CP, five were found to be novel. Ifosfamide preferentially underwent N-dechloroethylation, the pathway yielding 2-chloroacetaldehyde, while cyclophosphamide preferentially underwent ring-opening, the pathway yielding acrolein (AC). Additionally, S-carboxymethylcysteine and thiodiglycolic acid, two downstream IF and CP metabolites, were produced similarly in both IF- and CP-treated mice. This may suggest that other metabolites, perhaps precursors of thiodiglycolic acid, may be responsible for IF encephalopathy and nephropathy.
The Fanconi Syndrome
2009, Genetic Diseases of the Kidney
This chapter focuses on a group of congenital and acquired disorders that are not due to a single solute transporter defect but rather appear to result from more generalized and heterogeneous dysfunctions of the entire proximal tubule. The complete or classical Fanconi syndrome may be defined as an impairment of proximal tubule reabsorption of sodium, bicarbonate, potassium, phosphate, glucose, amino acids, uric acid and low-molecular-weight proteins, and peptides, as well as other organic solutes. Cystinosis is the most common cause of the Fanconi syndrome in childhood and serves as a prototype of this syndrome. Cystinosis is a lysosomal storage disorder where the defective cystine transporter, cystinosin, fails to extrude cystine from the lysosomes. Fumarylacetoacetate hydrolase (FAH) in liver and kidney is the last enzyme in the tyrosine catabolic pathway. Patients with mutations of FAH have tyrosinemia and develop the Fanconi syndrome after ingestion of tyrosine or phenylalanine. One of the accumulated metabolites, succinylacetone, is nephrotoxic but may not be the sole agent. Over the short term, the Fanconi syndrome is reversible upon removal of tyrosine or phenylalanine from the diet. Heavy metals (cadmium, mercury, lead, chromium, and platinum) are transported by the proximal tubule and are also toxic to the same epithelia. The kidney is a prime target of heavy metal toxicity because of its ability to accumulate metals. In humans, chronic exposure can result in a range of disorders from the Fanconi syndrome to renal failure. Cadmium-induced Fanconi syndrome usually only occurs after years of industrial exposure, while lead-induced Fanconi syndrome can occur after a large acute exposure or after prolonged chronic low levels of exposure.
Morin mitigates ifosfamide induced nephrotoxicity by regulation of NF-kappaB/p53 and Bcl-2 expression
2022, Biotechnic and Histochemistry
Lycopene abrogates ifosfamide-induced fanconi syndrome in albino rats
2021, Journal of Medical Sciences (Taiwan)
Pharmacokinetics in children with chronic kidney disease
2020, Pediatric Nephrology

View all citing articles on Scopus

View full text

Pharmacology lettersEvidence of renal metabolism of ifosfamide to nephrotoxic metabolites

Abstract

Pharmacology letters
Evidence of renal metabolism of ifosfamide to nephrotoxic metabolites